Article
Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis.
Thrombosis and haemostasis - 1 Feb 2007
de Bruijne Emile L E, Darwish Murad Sarwa, de Maat Moniek P M, Tanck Michael W T, Haagsma Elizabeth B, van Hoek Bart, Rosendaal Frits R, Janssen Harry L A, Leebeek Frank W G
Abstract excerpt
Splanchnic vein thrombosis (SVT) has been associated with a hypercoagulable state. Thrombin-activatable fibrinolysis inhibitor (TAFI) may contribute to a hypercoagulable state, and therefore we were interested in the role of TAFI in SVT. Since the disease is frequently associated with liver insufficiency, which affects plasma levels of TAFI, we studied the role of variation in the TAFI gene in SVT. In a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.